Prostate Cancer - Results from #680

Docetaxel versus androgen receptor signaling inhibitor (ARSI) against chemo-naïve castration-resistant prostate cancer (CRPC): propensity score matched analysis in real world. June 26, 2024

Characterization of Wnt Signaling Pathway Aberrations in Metastatic Prostate Cancer. June 26, 2024

Uptake of Same-Day Discharge for Patients Undergoing Robot-Assisted Radical Prostatectomy in the Michigan Urological Surgery Improvement Collaborative. June 26, 2024

Rare histologic transformation of a CTNNB1 (β-catenin) mutated prostate cancer with aggressive clinical course. June 25, 2024

The spectrum of cutaneous toxicities related to novel genitourinary cancer therapies. June 25, 2024

Diagnostic Accuracy of 18F-Prostate Specific Membrane Antigen (PSMA) PET/CT Radiotracers in Staging and Restaging of Patients With High-Risk Prostate Cancer or Biochemical Recurrence: An Overview of Reviews. June 25, 2024

Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study). June 25, 2024

Androgen Receptor Splice Variant 7 in Asian Patients With Metastatic Castration-Resistant Prostate Cancer. June 25, 2024

Increasing Diversity, Equity, and Inclusion in Urology Residency Recruitment: Recommendations From the Society of Women in Urology June 24, 2024

Financial Toxicity Among Patients With Metastatic Prostate Cancer: A Mixed Methods Approach to Identify Effective Interventions. June 24, 2024

Prostate Cancer Risk Stratification by Digital Histopathology and Deep Learning. June 24, 2024

Development of an effective predictive screening tool for prostate cancer using the ClarityDX machine learning platform. June 24, 2024

Reasons for Discordance between 68Ga-PSMA-PET and Magnetic Resonance Imaging in Men with Metastatic Prostate Cancer. June 24, 2024

Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies. June 24, 2024

Association of Tumor Genetics with Outcomes in Patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 June 21, 2024

Transition from Transrectal to Transperineal MRI-Fusion Prostate Biopsy Does Not Comprise Detection Rates of Clinically Significant Prostate Cancer at a Tertiary Care Center. June 21, 2024

Prognostic Impact and Clinical Implications of Adverse Tumor Grade in Very Favorable Low- and Intermediate-Risk Prostate Cancer Patients Treated with Robot-Assisted Radical Prostatectomy: Experience of a Single Tertiary Referral Center. June 21, 2024

The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer. June 21, 2024

Corrigendum to "Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial" [Eur. Eurol. 84(2) (2023) 156-163]. June 21, 2024

Five-year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial. June 21, 2024

Page 35 of 1435